SIM
AUPH icon

Spark Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Spark Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,000
Closed -$71K – 570
2019
Q1 		$71K Buy
+11,000
New +$73K ﹤0.01% 595
2018
Q4 		– Sell
-18,000
Closed -$118K – 665
2018
Q3 		$118K Buy
+18,000
New +$101K 0.01% 600
2018
Q1 		– Sell
-33,700
Closed -$153K – 602
2017
Q4 		$153K Buy
+33,700
New +$187K 0.01% 596

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Spark Investment Management's AUPH Position: Q2 2019 in Review

Spark Investment Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2019, closing a stake of 11,000 shares — an estimated $71K sold.

Spark Investment Management first reported a position in AUPH in Q4 2017 and held it in 3 quarters. The position peaked at $153K in Q4 2017. 73 funds tracked by Wall St. Rank hold AUPH as of Q2 2019.

  • Spark Investment Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Spark Investment Management sold 11,000 Aurinia Pharmaceuticals shares in Q2 2019, an estimated $71K.
  • Spark Investment Management first reported a position in Aurinia Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Spark Investment Management's Aurinia Pharmaceuticals position peaked at $153K in Q4 2017.
  • 73 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.